Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
- 22 February 2019
- journal article
- case report
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 53 (3) , 223-230
Abstract
Metastatic paraganglioma treatment options are limited. Peptide receptor radionuclide therapy (PRRT) has been introduced as a novel management option for mKeywords
Funding Information
- National Institute of Child Health and Human Development (Z1AHD008735)
This publication has 34 references indexed in Scilit:
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-OctreotateJournal of Nuclear Medicine, 2013
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resectionsEuropean Journal of Cancer, 2012
- Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)Hormone and Metabolic Research, 2012
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine TumorsClinical Cancer Research, 2010
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine TumorsJournal of Nuclear Medicine, 2009
- 131I-MIBG Therapy in metastatic phaeochromocytoma and paragangliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Malignant Pheochromocytomas and ParagangliomasAnnals of the New York Academy of Sciences, 2006
- Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant PheochromocytomaThe Journal of Clinical Endocrinology & Metabolism, 2005
- Malignant pheochromocytoma: current status and initiatives for future progressEndocrine-Related Cancer, 2004